| Literature DB >> 35490224 |
Niklas Deventer1, Tymoteusz Budny2, Georg Gosheger2, Marieke de Vaal2, Jana Burkhardt3, Nils Deventer3.
Abstract
BACKGROUND: The aneurysmal bone cyst (ABC) is a benign, but locally aggressive cystic lesion of the bone. It usually occurs in the metaphysis of long bones of adolescents and young adults but can also affect the pelvis.Entities:
Keywords: Aneurysmal bone cyst; Polidocanol injection; Polidocanol instillation
Mesh:
Substances:
Year: 2022 PMID: 35490224 PMCID: PMC9055713 DOI: 10.1186/s12891-022-05362-1
Source DB: PubMed Journal: BMC Musculoskelet Disord ISSN: 1471-2474 Impact factor: 2.562
Overview of the study collective
| Gender | Age | Localization | Volume in cm | Enneking classification | Rastogi classification | Treatment | Residual volume in cm | Additional treatment | Recurrence/persistent disease | Necessity of treatment | Complications | Number of instilations | Second recurrence | Follow-up (months) | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | female | 49 | sacrum | 8 | aggressive | not applicable | intralesional curettage + PMMA | – | No | recurrence | no | none | – | no | 11 |
| 2 | male | 13 | ischiium | 12 | active | not applicable | intralesional curettage + PMMA | – | no | recurrence | no | none | – | no | 28 |
| 3 | female | 15 | pubis | 38,1 | aggressive | not applicable | intralesional curettage + bone substitute | – | no | no | no | none | – | no | 36 |
| 4 | female | 18 | ilium | 11,9 | active | not applicable | intralesional curettage + bone substitute | – | no | no | no | none | – | no | 7 |
| 5 | female | 15 | ilium | 42 | active | not applicable | biopsy + watch and wait | – | no | no | no | none | – | no | 12 |
| 6 | male | 11 | ischium | 45,7 | aggressive | not applicable | marginal resection and reconstruction with PMMA | – | no | persistent disease | no | healing disorder | – | no | 23 |
| 7 | female | 12 | sacrum | 35 | aggressive | not applicable | marginal resection | – | embolization | persistent disease | no | none | – | no | 44 |
| 8 | female | 9 | ilium | 27,7 | active | not applicable | intralesional curettage + bone substitute | – | no | recurrence | yes | none | yes | 100 | |
| 9 | male | 42 | pubis | 66,9 | aggressive | not applicable | intralesional curettage + PMMA | – | embolization | recurrence | yes | none | – | no | 136 |
| 10 | male | 11 | ilium | 222,6 | active | not applicable | intralesional curettage + PMMA | – | embolization | persistent disease | yes | healing disorder | – | no | 89 |
| 11 | female | 14 | ilium | 43,8 | active | I | instillation of polidocanol | 0 | no | no | no | none | 3 | no | 59 |
| 12 | female | 16 | pubis | 106 | aggressive | I | Instillation of polidocanol | 9,1 | no | persistent disease | no | none | 7 | no | 37 |
| 13 | male | 16 | pubis | 40,1 | aggressive | I | Instillation of polidocanol | 1,94 | embolization | persistent disease | yes | none | 7 | no | 50 |
| 14 | male | 16 | pubis | 20,2 | aggressive | III | Instillation of polidocanol | 14,69 | no | persistent disease | no | none | 8 | no | 51 |
| 15 | female | 16 | pubis | 56,7 | aggressive | III | Instillation of polidocanol | 31,27 | embolization | persistent disease | no | none | 6 | no | 58 |
| 16 | female | 10 | ilium | 113,3 | aggressive | III | Instillation of polidocanol | 58,98 | embolization | persistent disease | no | none | 10 | no | 62 |
| 17 | female | 16 | sacrum | 32,7 | aggressiv | IV | Instillation of polydocanol | 32,44 | embolization | persistent disease | no | none | 6 | no | 50 |
Fig. 1a-e Manifestation of an ABC in the left ilium and ischium: simple radiograph (a) and MRI scan (b); preoperative angiography without embolization (c); radiograph after intralesional curettage and cement augmentation (d), MRI scan 24 months after operation with small residual cystic element (e)
Fig. 2a-e ABC of the right ilium of a 15-year-old patient: simple radiograph (a); MRI scan (b); transarterial embolization and percutaneous sclerotherapy (c), simple radiographs 6 weeks (left) and 24 months after the sixth and last instillation (right; d); MRI scan 24 months after the last sclerotherapy with constant residual cystic elements (e)